HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Venkatakrishnan, K. Articles by Greenblatt, D. J. Search for Related Content PubMed PubMed Citation Articles by Venkatakrishnan, K. Articles by Greenblatt, D. J. Social Bookmarking                         What's this?

Kinetics and Dynamics of Intravenous Adinazolam, N-Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers

From the Department of Pharmacology and Experimental Therapeutics, the Department of Neurology, and the Division of Clinical Pharmacology, Tufts University School of Medicine and Tufts-New England Medical Center, Boston.

The pharmacokinetics and pharmacodynamics of adinazolam mesylate (10 mg), N-desmethyl adinazolam mesylate (NDMAD, 10 mg), and alprazolam (1 mg) were investigated in 9 healthy male subjects in a randomized, blinded, single-dose, 4-way crossover study. All drugs were intravenously infused over 30 minutes. Plasma adinazolam, NDMAD, and alprazolam concentrations, electroencephalographic (EEG) activity in the ß (12-30 Hz) range, performance on the Digit Symbol Substitution Test (DSST), and subjective measures of mood and sedation were monitored for 12 to 24 hours. Mean pharmacokinetic parameters for adinazolam, NDMAD, and alprazolam, respectively, were as follows: volume of distribution (L), 106, 100, and 77; elimination half-life (hours), 2.9, 2.8, and 14.6; and clearance (mL/min), 444, 321, and 84. More than 80% of the total infused adinazolam dose was converted to systemically appearing NDMAD. All 3 benzodiazepine agonists significantly increased ß EEG activity, with alprazolam showing the strongest agonist activity and adinazolam showing the weakest activity. Alprazolam and NDMAD significantly decreased DSST performance, whereas adinazolam had no effect relative to placebo. Adinazolam, NDMAD, and alprazolam all produced significant observer-rated sedation. Plots of EEG effect versus plasma alprazolam concentration demonstrated counterclockwise hysteresis, consistent with an effect site delay. This was incorporated into a kinetic-dynamic model in which hypothetical effect site concentration was related to pharmacodynamic EEG effect via the sigmoid E_max model, yielding an effect site equilibration half-life of 4.8 minutes. The exponential effect model described NDMAD pharmacokinetics and EEG pharmacodynamics. The relation of both alprazolam and NDMAD plasma concentrations to DSST performance could be described by a modified exponential model. Pharmacokinetic-dynamic modeling was not possible for adinazolam, as the data did not conform to any known concentration-effect model. Collectively, these results indicate that the benzodiazepine-like effects occurring after adinazolam administration are mediated by mainly NDMAD.

Key Words: Adinazolam • N-desmethyl adinazolam • alprazolam • electroencephalography • Digit Symbol Substitution Test • pharmacokinetics • pharmacodynamics

Address for reprints: David J. Greenblatt, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Nutt, F. Mandel, and F. Baldinetti Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model J Psychopharmacol, November 1, 2009; 23(8): 867 - 873. [Abstract] [PDF]

				M. M. McCarthy, E. N. Brown, and N. Kopell Potential Network Mechanisms Mediating Electroencephalographic Beta Rhythm Changes during Propofol-Induced Paradoxical Excitation J. Neurosci., December 10, 2008; 28(50): 13488 - 13504. [Abstract] [Full Text] [PDF]

				G. Kotzalidis, I. Pacchiarotti, G. Manfredi, V. Savoja, C. Torrent, L. Mazzarini, C. Tatarelli, B. Amann, S. Di Marzo, J. Sanchez-Moreno, et al. Ethical questions in human clinical psychopharmacology: should the focus be on placebo administration? J Psychopharmacol, August 1, 2008; 22(6): 590 - 597. [Abstract] [PDF]

				D. J. Greenblatt, E. Legangneux, J. S. Harmatz, E. Weinling, J. Freeman, K. Rice, and G. K. Zammit Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J. Clin. Pharmacol., December 1, 2006; 46(12): 1469 - 1480. [Abstract] [Full Text] [PDF]